Understanding how a specific protein affects immune responses and tolerance

Role of autophagy-related protein Vps34 in antigen presentation and self-tolerance

NIH-funded research Vanderbilt University Medical Center · NIH-10455082

This study is looking at a protein called Vps34 to see how it helps our immune system show important signals to T cells, which are key players in fighting off infections and keeping our bodies healthy, with the hope of finding better ways to treat immune-related diseases.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionVanderbilt University Medical Center NIH-funded
Lab location1 site (Nashville, United States)
Project IDNIH-10455082 on NIH RePORTER

What this research studies

This research investigates the role of a protein called Vps34 in the immune system, particularly how it helps present antigens to T cells, which are crucial for immune responses. By studying the processes of autophagy and antigen presentation, the researchers aim to understand how these mechanisms can be manipulated to improve tolerance to self-antigens and enhance responses to foreign pathogens. The approach includes using animal models to observe the effects of Vps34 deficiency on immune cell function and development. The ultimate goal is to find new ways to prevent or treat diseases related to immune dysfunction.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals with autoimmune diseases or those requiring organ transplants, as they may benefit from improved immune tolerance.

Not a fit: Patients with conditions unrelated to immune system dysfunction or those not requiring immune modulation may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new strategies for developing vaccines and therapies that improve immune tolerance and response.

How similar studies have performed: Previous research has shown promising results in manipulating immune pathways for better tolerance and response, indicating that this approach has potential for success.

Where this research is happening

Nashville, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.